Key result
Atorvastatin plus ezetimibe resolves severe xanthomatosis in dysbetalipoproteinemia with novel APOE variants.
Why the study?
An unusual form of dysbetalipoproteinemia with severe ApoE deficiency and early clinical manifestations requires precise diagnosis and therapeutic guidance.
Case Report (n=1)
A rare early-onset presentation of severe dysbetalipoproteinemia caused by novel biallelic APOE variants was successfully managed with atorvastatin and ezetimibe.
Answers are grounded in this paper and cite their sources.
May prompt APOE sequencing in early severe xanthomatosis; extends variant spectrum but leaves treatment implications open.
We report an 18-year-old woman with severe dysbetalipoproteinemia and apolipoprotein E (ApoE) deficiency. Laboratory evaluations showed total cholesterol level: 11.76 mmol/L (454.8 mg/dL); triglyceride (TG) level: 2.90 mmol/L (256.9 mg/dL), and a low-density lipoprotein cholesterol level: 8.18 mmol/L (316.3 mg/dL). Lipoprotein electrophoresis revealed elevated very-low-density lipoprotein (VLDL) cholesterol and VLDL TGs of 5.69 mmol/L (220 mg/dL) and 1.73 mmol/L (153 mg/dL), respectively. She had severe xanthomatosis, which cleared after lipid-lowering but recurred when medications were stopped. Her lipids markedly improved and remained at cholesterol targets on both atorvastatin 40 mg and ezetimibe 10 mg a day. Whole exome sequencing showed 2 novel APOE variants, c.43 + 3delA and c.754G>T, p.(Glu252Ter), with corresponding very-low levels of plasma apolipoprotein E. Familial segregation revealed that the proband carried monogenic biallelic variants in APOE and first-degree relatives heterozygous for the APOE variants. This case report highlights an unusual form of dysbetalipoproteinemia with severe ApoE deficiency associated with early onset of clinical manifestations, elevated remnant cholesterol, and a favorable therapeutic response to a combination of statins and ezetimibe.
No takes yet. Share an insight, caveat, or question.
Pek et al. (2026) conducted a case report in Severe dysbetalipoproteinemia and apolipoprotein E (ApoE) deficiency (n=1). Whole exome sequencing and lipid-lowering therapy (atorvastatin and ezetimibe) was evaluated. Whole exome sequencing identified 2 novel APOE variants in an 18-year-old woman with dysbetalipoproteinemia, whose severe xanthomatosis resolved with atorvastatin and ezetimibe.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: